Ropinirole prolonged release: In advanced Parkinson's disease

CNS Drugs

Volumn 23, Issue 1, 2009, Pages 81-90

  Weber, Juliane ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug profiles; Controlled release drugs; Parkinson's disease, treatment; Ropinirole, adverse reactions; Ropinirole, pharmacodynamics; Ropinirole, pharmacokinetics; Ropinirole, therapeutic use

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CIPROFLOXACIN; CYTOCHROME P450 1A2; CYTOCHROME P450 3A; DIGOXIN; DOMPERIDONE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; ENOXACIN; FLUVOXAMINE; LEVODOPA; PLACEBO; REQUIP DEPOT; REQUIP LP; REQUIP MODUTAB; REQUIP PROLIB; REQUIP XL; ROPINIROLE; THEOPHYLLINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; DYSKINESIA; HALLUCINATION; HUMAN; HYPOTENSION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SOMNOLENCE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; INDOLES; PARKINSON DISEASE;

EID: 57449088458     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/0023210-200923010-00006     Document Type: Review

References (23)

1. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care (NICE clinical guideline 35) [online]. Available from URL: http://www.nice.org.uk/nicemedia/ pdf/cg035niceguideline.pdf [Accessed 2007 Sep 18]
2. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001 Jun; 56 (11 Suppl. 5): S1-88
3. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004 May 29; 363: 1783-93
4. Pahwa R, Factor SA, Lyons KE, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 11; 66 (7): 983-95
5. National Collaborating Centre for Chronic Conditions. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians, 2006
6. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007 Apr 3; 68 (14): 1108-15
7. Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease. Clin Ther 2007 Dec; 29 (12): 2654-66
8. Tompson D, Oliver-Willwong, R. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease. Clin Neuropharmacol. Epub 2008 Oct 23
9. GlaxoSmithKline UK. Requip tablets: UK summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinter-Friendly.asp?documentid=2056 [Accessed 2008 Nov 17]
10. GlaxoSmithKline. Ropinirole 2, 3, 4 and 8 mg prolonged-release tablets: EU mutual recognition summary of product characteristics. GlaxoSmithKline, 2007 Nov 27
11. GlaxoSmithKline. Requip® XL™ (ropinirole extended-release tablets): US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us_requipxl.pdf [Accessed 2008 Nov 17]
12. Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 2000 Jul; 60 (1): 115-37
13. Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev 2005; 11 (3): 253-72
14. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000 Oct; 39 (4): 243-54
15. Stocchi F, Stover NP, Giorgi L. Ropinirole 24-hour prolonged release as adjunct to L-dopa in patients with advanced Parkinson's disease: efficacy according to baseline depression score [abstract no. 295]. Mov Disord 2007; 22 Suppl. 16: S90
16. Hersh BP, Stover NP, Elmer LW, et al. Early efficacy of adjunctive ropinirole 24-hour in patients with advanced PD [abstract no. M-78]. Ann Neurol 2007; 62 Suppl. 11: S35
17. Isaacson S, Pahwa R, Earl N. Ropinirole 24-hour prolonged-release adjunctive therapy improves cardinal symptoms in patients with advanced Parkinson's disease not optimally controlled with L-dopa [abstract no. 2.238]. Parkinsonism Relat Disord 2007; 13 Suppl. 2: S108
18. Sethi KD, Stocchi F, Giorgi L. Ropinirole 24-hour prolonged release in advanced Parkinson's disease: relationship between treatment response and disease severity [abstract no. 301]. Mov Disord 2007; 22 Suppl. 16: S92-3
19. Stocchi F, Hunter B, Giorgi L, et al. An evaluation of symptom control in patients with advanced PD receiving adjunctive ropinirole 24-hour prolonged release versus ropinirole immediate release: results from the PREPARED study [abstract]. 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23-26; Madrid
20. Stocchi F, Hunter B, Giorgi L, et al. Adjunctive ropinirole 24-hour prolonged release compared with ropinirole immediate release in patients with advanced Parkinson's disease (PD): the PREPARED study [abstract]. 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23-26; Madrid
21. Schapira AHV, Stocchi F, Hunter B, et al. Adjunctive ropinirole 24-hour prolonged release compared with adjunctive ropinirole immediate release in patients with advanced PD: results from a per-protocol analysis of the PREPARED study [abstract]. 12th Congress of the European Federation of Neurological Societies; 2008 Aug 23-26; Madrid
22. Watts RL, Sethi KD, Pahwa R, et al. Ropinirole 24-hour prolonged release delays the onset of dyskinesia compared with carbidopa/levodopa in patients with Parkinson's disease treated with levodopa [abstract no. P1138]. Eur J Neurol 2007; Suppl. 1: 65
23. Educational highlights from data presented at the XVIIth World Federation of Neurology (WFN) World Congress on Parkinson's Disease; 2007 December 9-13; Amsterdam [online]. Available from URL: http://clienti.tio.ch/img_articoli/ 20080925_233206_WFNRopinirole-v2.02007.pdf [Accessed 2008 Dec 8]